Recordati has reported a healthy rise in revenues for the first half of the year, up 8.9%, boosted by international sales.

Turnover came in at 379.3 million euros, and while the Italian drugmaker did not give many details about the figures, it noted that pharmaceutical sales grew 10.1% while chemicals sales were down. Growth is due mainly to Recordati’s international business which increased 12.5%, helped by recently-acquired Yeni Ilac of Turkey and Czech drugmaker Herbacos-Bofarma, while in Italy sales are up 1.2%.

Chief executive Giovanni Recordati said the results “are evidence of the validity of our strategy to grow our pharmaceutical operations…and the expansion of our direct presence in the European pharmaceutical markets”.

Amdipharm deal
The company has also signed a deal with Amdipharm to market TransAct LAT, a pain relief transdermal patch containing flurbiprofen, in Italy and Portugal. The product is already on sale in these markets and has sales of approximately 13 million euros.